Search Trials

Order


Status


868 results


Not Yet Recruiting

Start date: July 1, 2022

Approximately 15-24 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells … Read More

BCM Role: Lead Sponsor

Not Yet Recruiting

Start date: Oct. 1, 2021

Screening: All patients undergoing either elective or emergency cardiac surgery will be screened against the eligibility criteria. Research Sample Collection: Blood and urine will be collected for the first 48 … Read More


Not Yet Recruiting

Start date: Oct. 1, 2021

Endoscopic Ultrasound (EUS) is a minimally invasive procedure used by gastroenterologists to examine pancreatic masses and lesions. A fine needle is traversed through an endoscope and used to acquire tissue … Read More

BCM Role: Lead Sponsor

Not Yet Recruiting

Start date: Sept. 15, 2021

More treatments are needed to target insomnia in Veterans with Posttraumatic Stress Disorder. There is evidence to suggest that pimavanserin, a medication approved by the Food and Drug Administration for … Read More

BCM Role: Lead Sponsor

Not Yet Recruiting

Start date: Sept. 3, 2021

PBTC-059 is a multicenter, Phase I and Surgical study of the treatment HER2-specific CAR T cells for patients with refractory or recurrent ependymoma. Phase I The primary objectives of the … Read More

BCM Role: Collaborator

Not Yet Recruiting

Start date: Sept. 1, 2021

Earlier, healthy donors gave blood for us to make CD30.CAR-EBVST cells in the laboratory. These cells were grown and frozen and the investigators will select the donor which the investigators … Read More

BCM Role: Lead Sponsor

Not Yet Recruiting

Start date: Sept. 1, 2021

To make the T cells, the investigators will take the patient's blood and stimulate it with growth factors to make the T cells grow. Investigators will remove the CD7 gene … Read More

BCM Role: Lead Sponsor

Not Yet Recruiting

Start date: Sept. 1, 2021

Osteogenesis imperfecta (OI) is a heritable connective tissue disorder leading to frequent fractures and bone deformities. In about 90% of individuals with OI, the disease is caused by dominant mutations … Read More

BCM Role: Lead Sponsor

Not Yet Recruiting

Start date: Sept. 1, 2021

Urea cycle disorders (UCDs) are among the most common inborn errors of liver metabolism. With early diagnosis and improved treatments, the survival of individuals with UCDs has improved, and this … Read More

BCM Role: Lead Sponsor

Not Yet Recruiting

Start date: Sept. 1, 2021

Urea cycle disorders (UCDs) are among the most common inborn errors of liver metabolism. With early diagnosis and improved treatments, the survival of individuals with UCDs has improved, and this … Read More

BCM Role: Lead Sponsor